



LIVE WEBINAR

Hyperglycemia in pregnancy and beyond

18 October 2024
from 13.00 to 14.00 CEST

MeδEA
Medical Education Academy

Overview

The nature of pregnant women has changed in recent years: women are more likely to give birth at an older maternal age, and more women are likely to be obese when they become pregnant. Not only have older age and higher weight increased the number of women with pre-existing type 2 diabetes who become pregnant, they are also associated with an increased prevalence of gestational diabetes mellitus, which is long recognized as a global health concern. Perinatal morbidity and mortality in pregnancies complicated by diabetes mellitus is much higher than in the general obstetric population, proportionate to the level of glycemic control. In addition, a diagnosis of gestational diabetes mellitus increases the risk of cardiometabolic diseases (including type 2 diabetes) for both mother and child, in later life. Consequently it is vital that hyperglycemia is screened for in every woman in pregnancy, through oral glucose tolerance testing and individual consideration of risk factors for the condition (which involve ethnicity, previous history of high-birthweight babies, and family history of diabetes, for example). In developing world and/or marginalized community-based populations, optimum screening strategies are unclear. Consequently, there are unmet needs in real-world clinical care relating to awareness and implementation of guidelines for gestational diabetes screening and management. Follow-up screening of women with history of gestational diabetes is necessary to ensure timely identification of pre-diabetes and type 2 diabetes in these high-risk individuals.

Learning Objectives

After attending the live webinar participants will be able to:

1. Understand how to screen for hyperglycemia and diagnose gestational diabetes
2. Competently manage diabetes in pregnancy
3. Plan and deliver post-partum screening programs

Target Audience

Clinicians involved in endocrinology, particularly diabetes, pre-diabetes, fertility and pregnancy management, obesity management and general practice; midwives and nurses involved in pre-natal and post-natal care.

Language

English with simultaneous translation into Spanish and Chinese

Continuing Medical Education

The **Hyperglycemia in pregnancy and beyond** - Virtual, Italy, 18/10/2024 - 18/10/2024 organized by MedEA Medical Education Academy has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of **1.0 European CME credits** (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



The content of the “Hyperglycemia in pregnancy and beyond” has been certified by the CPD Certification Service as conforming to continuing professional development principles.



Registration

To register for free and watch the Webinar:

CLICK HERE
or SCAN



REGISTRATION IS FREE OF CHARGE

This educational programme is made possible thanks to an independent educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

CME Provider

MedEA Medical Education Academy

Senior Educational Programme Director: Flaminia Masprone

T 39 02 8295 8658

info@medeaacademy.com



Partnerships & Endorsements

Latin American Diabetes Association (ALAD)

Philippine College of Endocrinology, Diabetes, and Metabolism (PCEDM)



Con il patrocinio della Società Italiana di Diabetologia

International Committee

CLICK HERE

to view the members of the
International Committee

Hyperglycemia in pregnancy and beyond

Live Webinar: 18 October 2024 - from 13.00 to 14.00 CEST

- | | |
|-------|--|
| 13.00 | Introduction and aim of webinar
Nemencio A. Nicodemus Jr. (Philippines) |
| 13.05 | Type 2 diabetes management in pregnancy planning and pregnancy
Raffaella Buzzetti (Italy) |
| 13.25 | Safety, efficacy and role of metformin in treatment of hyperglycemia during pregnancy and beyond
Ernesto Maddaloni (Italy) |
| 13.45 | Panel discussion
N. Nicodemus, R. Buzzetti, E. Maddaloni |
| 13.55 | Closing remarks
Nemencio A. Nicodemus Jr. (Philippines) |
| 14.00 | End of the live webinar |

FACULTY DISCLOSURES

MedEA Medical Education Academy adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter).

We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of MedEA. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Raffaella Buzzetti

Declared receipt of grants and contracts from AstraZeneca Plc; receipt of honoraria or consultation fees from Eli Lilly Italia, Sanofi, Abbott, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Vertex; participation in company sponsored speaker's bureau of Eli Lilly, Sanofi, Abbott, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Vertex.

Ernesto Maddaloni

Declared receipt of honoraria for consultancy or speaker fees or support for participating in scientific meetings from Abbott, AstraZeneca, Eli-Lilly, MSD, MTD, Novo Nordisk, PikDare; declared that his presentation will include discussion of off-labeled or otherwise non-approved uses of products. Declared that he will convey this point to the audience as follows: Metformin might not be approved for gestational diabetes in some countries.

Nemencio A. Nicodemus Jr.

Declared no potential conflict of interest.

BIOGRAPHIES



Raffaella Buzzetti

Professor of Endocrinology
La Sapienza University of Rome
Head of the Diabetes Unit
Policlinico Umberto I Hospital
Rome, Italy

Raffaella Buzzetti is Professor of Endocrinology at the Department of Experimental Medicine, Sapienza University of Rome and has been leading the Diabetes Unit at Policlinico Umberto I Hospital since 2017, where she provides integrated care for diabetes and metabolic diseases. Beside her clinical activity, Professor Buzzetti coordinates the II semester of the IV year in Medicine and Surgery at Sapienza University, while lecturing on courses of “Integrated pathology III” and “Medical-Scientific Methodology VIII”. Professor Buzzetti graduated in Medicine and Surgery, where she specialized in “Endocrinology” and “Medical Genetics” at Sapienza, University of Rome and was a Research Fellow at Queen Mary College, St. Bartholomew’s Hospital, London. Professor Buzzetti’s research interests include genetic susceptibility to polygenic diseases such as type 1 diabetes, pathogenesis and clinical features of type I diabetes and adult-onset autoimmune diabetes; she is clinical lead for phase II and III studies. She has authored and co-authored 284 publications (H. Index Scopus 53), with 78 of them in the last 3 years. Professor Buzzetti is a member of the editorial boards for Diabetes Metabolism Research and Reviews, PLOS ONE and is also a member of the board of the National Committee of Medical Research Evaluators.

BIOGRAPHIES



Ernesto Maddaloni

Assistant Professor of
Endocrinology and Diabetes
La Sapienza University of Rome
Rome, Italy

Ernesto Maddaloni, is currently Assistant Professor of Endocrinology and Diabetes at Sapienza University of Rome, Italy. He gained his MD, clinical specialty in Endocrinology and Diabetes and PhD in “Integrated Biomedical Sciences and Bioethics” at Campus Bio-Medico University of Rome. He has joined the Vascular Cell Biology Section of the Joslin Diabetes Center (Harvard Medical School) for a Post-Doctoral Research Fellowship in 2014 and the Diabetes Trial Unit of the University of Oxford in 2017 as a mentee of the European Foundation for the Study of Diabetes (EFSD) Future Leaders Mentorship Program, to actively pursuing his studies on clinical diabetes, cardiovascular outcomes and novel diabetes complications. His research interests focus on the study of adults with autoimmune diabetes and the interplay between vascular complications, bone health and autoimmunity. After the Sars-CoV2 infection outbreak, he has contributed also with original articles evaluating the strict relationship between diabetes and related comorbidities with Covid-19. Dr Maddaloni has been a study investigator and coordinator for several national and international clinical trials and has published as lead author in several top-ranked peer-reviewed international medical journals. His scientific achievements have been recognized with several awards, including the 2015 Albert Renold Fellowship from the European Foundation for the Study of Diabetes, the 2017 (under 32) and 2021 (under 35) Young Investigator Awards from the Italian Society of Endocrinology (SIE), the 2017 Early Investigator Award from the Endocrine Society (USA) and the 2020 Young (under 35) Investigator Award from the Italian Society of Diabetes (SID).

BIOGRAPHIES



Nemencio A. Nicodemus Jr.

Professor at the Department of
Biochemistry and Molecular Biology
University of the Philippines
College of Medicine
Clinical Professor at the Division of
Endocrinology, Diabetes and Metabolism
Department of Medicine
Philippine General Hospital
Manila, Philippines

Currently serving as Professor of the Department of Biochemistry and Molecular Biology at the University of the Philippines College of Medicine, and a Clinical Professor at the Division of Endocrinology, Diabetes and Metabolism of the Department of Medicine at the Philippine General Hospital, Dr Nemencio Nicodemus Jr. is also Vice Chair for Postgraduate Training and the departmental training officer. Nationally, Prof. Nicodemus is the Treasurer of the Philippine College of Physicians, President of the Philippine Association for the Study of Overweight and Obesity (PASOO) and a past President of the Philippine Thyroid Association and the Philippine Society of Endocrinology, Diabetes and Metabolism. An active and engaging lecturer, Dr Nicodemus has been invited to several regional and international conferences, including the International Society of Endocrinology, International Diabetes Federation and ASEAN Federation of Endocrine Societies as a resource speaker. Prof. Nicodemus has published several articles and book chapters on diabetes, thyroid and obesity. He is a member of the technical committee who oversee clinical practice guidelines on diabetes in pregnancy and thyroid disorders in pregnancy, including guidelines on recurrent pregnancy loss in the Philippines.

All MedEA Medical Education Academy programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of MedEA Medical Education Academy.

This educational program is made possible thanks to an independent educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.





Via Monte Napoleone, 8 - 20121, Milan, Italy
85 Great Portland Street, London, UK

medeaacademy.com

